{"product_id":"igf-1-des-2mg","title":"IGF-1 DES, 2mg","description":"\u003cdiv class=\"ZLzG0d ncoeY E8xBUb\" role=\"heading\" aria-level=\"3\" data-animation-nesting=\"\" data-sfc-cp=\"\" data-wiz-attrbind=\"aria-level=LbSt0e_h\/fLk2Md\" data-sfc-root=\"c\"\u003eKey Characteristics\u003c!--TgQPHdLbSt0e_3\/LL5gb|||[[2,[null,null,null,null,null,null,null,null,null,null,null,null,[351768,null,0]],[],null,1]]--\u003e\n\u003c\/div\u003e\n\u003cdiv data-bfc=\"\" class=\"\" data-sfc-cp=\"\" data-sfc-root=\"c\" data-ved=\"2ahUKEwiMz8Ps-8mXAxWQC4AAHYnGMd4Qi4wTegYIAggHEAg\" data-hveid=\"CAIIBxAI\"\u003e\n\u003cul class=\"XSq4R KI3fJ\" data-sfc-cp=\"\" data-sfc-root=\"c\" data-hveid=\"CAIIBxAJ\"\u003e\n\u003cli class=\"Z1qcYe\" data-sfc-cp=\"\" data-sfc-root=\"c\" data-hveid=\"CAIIBxAK\"\u003e\n\u003cspan class=\"iNqyIf\" data-sfc-cp=\"\" data-sfc-root=\"c\"\u003e\u003cstrong class=\"rQesXe MPyX\" data-sfc-cp=\"\" data-sfc-root=\"c\"\u003ePotency:\u003c!--TgQPHd|||[]--\u003e\u003c\/strong\u003e Roughly 2 to 10 times more potent than native IGF-1 in cellular assays due to significantly reduced binding to IGF-binding proteins (IGFBPs).\u003c!--TgQPHd|||[]--\u003e\u003c\/span\u003e\u003cspan\u003e \u003c\/span\u003e\u003c!--TgQPHd|||[]--\u003e\n\u003c\/li\u003e\n\u003cli class=\"Z1qcYe\" data-sfc-cp=\"\" data-sfc-root=\"c\" data-hveid=\"CAIIBxAP\"\u003e\n\u003cspan class=\"iNqyIf\" data-sfc-cp=\"\" data-sfc-root=\"c\"\u003e\u003cstrong class=\"rQesXe MPyX\" data-sfc-cp=\"\" data-sfc-root=\"c\"\u003eHalf-Life:\u003c!--TgQPHd|||[]--\u003e\u003c\/strong\u003e Very short half-life of about \u003cstrong class=\"rQesXe MPyX\" data-sfc-cp=\"\" data-sfc-root=\"c\"\u003e20 to 30 minutes\u003c!--TgQPHd|||[]--\u003e\u003c\/strong\u003e, leading to rapid, localized action near the injection site rather than long-lasting systemic distribution.\u003c!--TgQPHd|||[]--\u003e\u003c\/span\u003e\u003cspan\u003e \u003c\/span\u003e\u003c!--TgQPHd|||[]--\u003e\n\u003c\/li\u003e\n\u003cli class=\"Z1qcYe\" data-sfc-cp=\"\" data-sfc-root=\"c\" data-hveid=\"CAIIBxAU\"\u003e\n\u003cspan class=\"iNqyIf\" data-sfc-cp=\"\" data-sfc-root=\"c\"\u003e\u003cstrong class=\"rQesXe MPyX\" data-sfc-cp=\"\" data-sfc-root=\"c\"\u003eComparison to IGF-1 LR3:\u003c!--TgQPHd|||[]--\u003e\u003c\/strong\u003e Unlike \u003cspan data-sfc-cp=\"\" data-sfc-root=\"c\" data-wiz-uids=\"LbSt0e_15\"\u003e\u003cspan class=\"\"\u003e\u003ca class=\"H23r4e\" rel=\"noopener\" data-ved=\"2ahUKEwiMz8Ps-8mXAxWQC4AAHYnGMd4Qy_kOegYIAggHEBU\" data-hveid=\"CAIIBxAV\" href=\"https:\/\/palmettopeptides.com\/blogs\/news\/igf1-lr3-vs-igf1-des\" target=\"_blank\"\u003eIGF-1 LR3\u003c\/a\u003e\u003c\/span\u003e\u003c!--TgQPHd|||[[\u0026quot;https:\/\/palmettopeptides.com\/blogs\/news\/igf1-lr3-vs-igf1-des\u0026quot;,null,null,[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,[{\u0026quot;1218\u0026quot;:[16,null,null,null,[1]]}]],16,null,\u0026quot;IGF-1 LR3 vs IGF-1 DES: Comparative Analysis for Preclinical Research Protocols | Palmetto Peptides\u0026quot;,\u0026quot;IGF-1 LR3 vs IGF-1 DES: Comparative Analysis for Preclinical Research Protocols * Quick Answer. When researchers move beyond native IGF-1 and begin evaluating synthetic analogs for preclinical work, two peptides come up consistently: IGF-1 LR3 and IGF-1 DES. Both are engineered modifications of the native sequence designed to overcome specific limitations of standard IGF-1 — particularly its rapid sequestration by insulin-like growth factor binding proteins (IGFBPs). * IGF-1 LR3 vs IGF-1 DES: Choosing the Right Analog for Your Research. When researchers move beyond native IGF-1 and begin evaluating synthetic analogs for preclinical work, two peptides come up consistently: IGF-1 LR3 and IGF-1 DES. Both are engineered modifications of the native sequence designed to overcome specific limitations of standard IGF-1 — particularly its rapid sequestration by insulin-like growth factor binding proteins (IGFBPs). But they take different structural approaches to solving that problem, and those differences have real consequences for experimental design. This article compares IGF-1 LR3 and IGF-1 DES across the dimensions that matter most in a research context: structure, receptor selectivity, IGFBP interactions, half-life, and practical protocol considerations. * What Is IGF-1 DES (DES(1-3) IGF-1)? IGF-1 DES, also written as DES(1-3) IGF-1, is a truncated analog of native IGF-1 that lacks the first three N-terminal amino acids (Gly-Pro-Glu). The result is a 67-amino acid peptide — three amino acids shorter than native IGF-1 — with a molecular weight of approximately 7.4 kDa. This truncation is not synthetic in the traditional sense: a naturally occurring form of DES-IGF-1 has been identified in various tissue environments, including fetal brain and serum fractions, suggesting it may have physiological relevance as a local growth factor (Sara et al., 1986). The synthetic version is produced recombinantly for research purposes and mirrors this naturally observed truncated form. Why Remove the First Three Amino Acids? The N-terminal tripeptide Gly-Pro-Glu in native IGF-1 contributes to IGFBP binding affinity, particularly for IGFBP-1, IGFBP-2, and IGFBP-4. Removing it disrupts this interaction and reduces binding protein affinity, similar in principle to IGF-1 LR3 — but through a different structural mechanism. * Side-by-Side Structural Comparison. Feature. Native IGF-1. IGF-1 LR3. IGF-1 DES. Amino acids. 70. 83. 67. Molecular weight. ~7.6 kDa. ~9.1 kDa. ~7.4 kDa. Structural change. None (reference) N-terminal extension + R3 substitution. N-terminal truncation (loss of Gly-Pro-Glu) IGFBP affinity. High. ~1,000x reduced vs native. Moderately reduced. IGF-1R affinity. High. Slightly reduced. Higher than native. IGF-2R (M6PR) binding. Low. Low. Low. IR cross-reactivity. Low. Low. Low. Estimated half-life. ~10–20 min (free) ~20–30 hours. ~20–30 min. * Key Structural Difference: Addition vs. Truncation. This is the most fundamental distinction between the two analogs: IGF-1 LR3 is a longer molecule than native IGF-1 — it adds 13 amino acids to the N-terminus plus makes the R3 point substitution, creating an 83-aa peptide. IGF-1 DES is a shorter molecule — it removes 3 N-terminal amino acids, creating a 67-aa peptide. Both approaches reduce IGFBP binding, but via opposite structural strategies. The practical implications of this difference emerge most clearly when comparing receptor binding and half-life.\u0026quot;,\u0026quot;https:\/\/encrypted-tbn0.gstatic.com\/images?q\\u003dtbn:ANd9GcR20ckDP4udfEJix09CdMbuAhik_fik6E5iL8WqOPesy4DYr1NsGS_cNw02CCSTSmbYu2SU0HuXMfNnOeM\u0026quot;,\u0026quot;Palmetto Peptides\u0026quot;,\u0026quot;https:\/\/encrypted-tbn3.gstatic.com\/faviconV2?url\\u003dhttps:\/\/palmettopeptides.com\\u0026client\\u003dAIM\\u0026size\\u003d128\\u0026type\\u003dFAVICON\\u0026fallback_opts\\u003dTYPE,SIZE,URL\u0026quot;,[[1792546436081548,8391568,3727804041],null,null,null,null,[[2,9]]],null,\u0026quot;5174ed8b-12c6-4b7b-9660-8f77a95d8484\u0026quot;]]--\u003e\u003c\/span\u003e (which has an 83-amino-acid structure and a 20–30 hour half-life for systemic effects), IGF-1 DES clears quickly and is primarily studied for targeted local effects\u003cspan\u003e.\u003c\/span\u003e\u003c!--TgQPHd|||[]--\u003e\u003c\/span\u003e\u003cspan\u003e \u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e","brand":"ChemForge","offers":[{"title":"Default Title","offer_id":67777018101796,"sku":null,"price":159.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0102\/5107\/5620\/files\/igfdes.jpg?v=1792546573","url":"https:\/\/supplement-addiction.myshopify.com\/products\/igf-1-des-2mg","provider":"Iron Addiction Supplements","version":"1.0","type":"link"}